Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million

About this update from Cognizant Technology Solutions Corporation

[{"type":"text","content":"Cognizant will manage Gilead's global IT infrastructure while leading digital transformation initiatives designed to enhance overall client experience and enable faster time to market for Gilead products.\nTEANECK, N.J., July 24, 2023 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced an expansion of its relationship with Gilead Sciences (NASDAQ: GILD). Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases. Under the agreement, Cognizant will manage Gilead's global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation. The agreement includes renewal and expansion of Cognizant services for a total expected value of $800 million over the next five years. This collaboration is aimed at enabling Gilead to streamline various parts of its business with the goal of faster time to market of various medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer.\n\n \n \n \n \n \n \n\n \nCognizant anticipates leveraging the power of Generative AI to help enhance Gilead's customer service experience.The pharmaceutical industry has traditionally been slower to adopt digital transformation journeys compared with other industries. Gilead is an industry leader in embracing digital transformation in its business, having partnered with Cognizant for more than three years to adopt cutting-edge technologies designed to drive better business outcomes. This includes supporting enabling technologies for running business operations, new product launches and improving IT processes for efficient research, manufacturing, and commercialization of its products.\n\"Over the past three years, Cognizant has demonstrated quality delivery, adaptability and dedication to Gilead's success,\" said Marc Berson, Senior Vice President and Chief Information Officer at Gilead Sciences. \"Through this collaboration, Cognizant has provided critical expertise to progress our digital transformation journey while enabling stable, secure operations. This has allowed us to advance research and commercialization of transformative treatments for some of the world's most challenging diseases. We look forward to expanding this partnership to advance to the next phases of our capability roadmap.\"\nBui...

More updates from Cognizant Technology Solutions Corporation